Neuro, We know RD-1 dosing was completed sometime prior to the June 18 press release, so it doesn't look like they made the procedural changes in the 2100 mg cohort of RD-2 until after RD-1 dosing was completed. If so, that means there were no procedural changes made in RD-1.
Therefore, our only hope for not seeing the same worthless data 'mush' in RD-1 that was seen in RD-2 is if the factors causing the problem were particular to only RD-2 (anxious patients and loose masks). If those factors were common to both trials, then the RD-1 data is likely 'mush'.
Market Data 
Markets 
AI
